SECmeres Beat Small EVs in 26-Patient Alzheimer’s Blood RNA Study
Updated
Updated · Nature.com · Jun 22
SECmeres Beat Small EVs in 26-Patient Alzheimer’s Blood RNA Study
1 articles · Updated · Nature.com · Jun 22
Summary
Researchers identified sub-50 nm “SECmeres” in human brain and blood and found their RNA signatures separated neuropathologically confirmed Alzheimer’s cases from controls more strongly than small extracellular vesicles.
In 26 subjects—10 with Alzheimer’s and 16 controls—SECmeres yielded 21 discriminatory RNAs at FDR below 0.01, versus 11 for small EVs, while large EVs showed no significant differences.
Single-cell deconvolution linked SECmeres mainly to brain endothelial cells at the blood-brain barrier, while small EVs carried RNA from more diverse brain cell types, suggesting distinct biological sources.
The team also introduced a 60-minute isolation method, SECrifuge, reporting more than 10-fold enrichment and higher reproducibility than ultracentrifugation for low-volume blood and brain samples.
The study is presented as proof of concept rather than a clinical test, with authors calling for larger blinded trials and validation in living patients before diagnostic use.
Will new 'SECmere' blood tests prove more critical than AI-driven MRI scans for early Alzheimer's detection?
Could these newly found nanoparticles unlock blood tests for other brain diseases like Parkinson's or ALS?
SECmeres: A Breakthrough Blood Biomarker Offering Superior Early Detection and Monitoring of Alzheimer’s Disease
Overview
In June 2026, researchers from the Icahn School of Medicine at Mount Sinai published a groundbreaking study in Nature Communications, unveiling SECmeres as a new and distinct class of extracellular vesicles. These SECmeres are much smaller than traditional vesicles and have a unique protein and lipid composition, allowing them to carry specific molecular cargo. Identified as superior biomarkers for Alzheimer’s disease, SECmeres offer new hope for earlier and more accurate detection of the condition. This discovery marks a major step forward in Alzheimer’s diagnostics, promising more reliable and accessible testing for patients.